News

Vertex Pharmaceuticals (NasdaqGS:VRTX) received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle cell disease and beta thalassemia. The company also signed a Letter of Intent with Canadian national payers that outlines commercial access terms for ALYFTREK, its next generation cystic fibrosis therapy. These updates arrive as Vertex Pharmaceuticals trades around $485.39 and remains closely watched after a 140.0% return over the past 5 years and a...

Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology. On a conference call announcing the deal, Vertex CEO

It's been a volatile year for the company, but don't let that scare you away.

It is getting acquired by a larger firm in the sector.

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

With its lead drug driving rapid growth and three more on deck, the biotech is betting it can outrun future competition and a history of volatility.

A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.

Additional blockbuster drugs may be on the horizon.

Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the best QQQ Stocks to invest in. On July 1, Vertex Pharmaceuticals announced that the US FDA approved the expanded use of its genetic therapy, CASGEVY, to treat children as young as 2 years old. This makes it the first and only approved gene therapy for patients of this […]

Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire it. Vertex’s $10 Billion All-Cash Bid Fuels the Surge The catalyst arrived after the market close on July 6: Vertex agreed to buy Crinetics for approximately $10 ... Why Crinetics Stock Soared 99% This Week

CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA,” ... Jim Cramer Says Biotech is The Hottest Group in The Market Right Now

International Biotechnology Trust (LSE:IBT) portfolio manager Ailsa Craig joined Proactive's Stephen Gunnion to discuss the surge in biotech M&A activity, following Vertex Pharmaceuticals' acquisition of Crinetics at a 102% premium. Craig said the deal wave reflects a structural dynamic: most new drugs now originate from biotech, while large pharmaceutical companies face a significant wave of patent expiries and hold substantial cash resources. Vertex's move into rare diseases and chronic therapies makes strategic sense as it diversifies beyond its cystic fibrosis franchise — and the premium paid reflected Crinetics' strong independent position. "They would be perfectly happy to stay independent. And Vertex had to pay up if they wanted to buy them," Craig said. She outlined how IBT evaluates investments using many of the same criteria as pharma business development teams — focusing on chronic therapies, attractive valuations, strong intellectual property and companies capable of remaining independent, making them compelling acquisition targets. Around 40% of IBT's portfolio currently meets these criteria, compared with around 10% of its benchmark - a positioning Craig believes leaves the trust well placed to benefit from continued industry consolidation. Visit the Proactive YouTube channel for more interviews with leading companies and investment experts. If you enjoyed this video, please like, subscribe to the channel and enable notifications so you never miss future content. #InternationalBiotechnologyTrust #Biotech #Biotechnology #AilsaCraig #HealthcareInvesting #BiotechStocks #Pharma #Vertex #Crinetics #MergersAndAcquisitions #Investing #StockMarket #LifeSciences #PatentExpiry #HealthcareInnovation #ProactiveInvestors

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks.

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best healthcare stocks on our list. TheFly reported on July 2 that UBS analyst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The analyst noted that […]

Vertex Pharmaceuticals stock has delivered a strong 163.3% return over the past 5 years, and the latest Discounted Cash Flow (DCF) intrinsic value estimate now points to meaningful upside relative to the current share price, even though market based valuation checks look more balanced. Over 5 years, a 163.3% total return suggests investors have already priced in a lot of success for Vertex Pharmaceuticals, which raises the bar for any further potential upside. The planned US$10b acquisition...

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.

Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.

Vertex Pharmaceuticals (VRTX) has moved into the spotlight after agreeing to acquire Crinetics Pharmaceuticals for about $10 billion in cash, a rare disease focused deal that immediately broadens its endocrinology footprint. See our latest analysis for Vertex Pharmaceuticals. Vertex Pharmaceuticals' latest share price of US$522.25 sits close to recent highs, with a 30 day share price return of 16.88% and a 1 year total shareholder return of 11.98%, adding to a 163.32% total shareholder return...

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about US$10b, reigniting takeover speculation across the obesity drug sector. Following this deal, Viking Therapeutics (NasdaqCM:VKTX) has drawn fresh attention as a possible M&A target. Investor focus is increasing on upcoming data for VK2735 and the recently initiated Phase 1 trial of VK3019. Viking Therapeutics sits at the intersection of obesity and metabolic drug development, an area that has attracted large capital...

This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.

CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.

Investors favored companies benefiting from biotech deals, rising power demand from AI data centers, and cost-cutting efforts to improve profits.

The drugmaker is paying up for a new growth engine. Is the price disciplined?

Crinetics stock nearly doubled after Vertex agreed to buy it for $10 billion. What's behind the deal, and is it worth it?

Vertex Pharmaceuticals (VRTX) closed at $522.25 in the latest trading session, marking a -1.39% move from the prior day.

Vertex Pharmaceuticals (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals for US$10b. The deal adds a marketed rare disease drug and moves Vertex into endocrinology as a new business area. The transaction is positioned to expand Vertex's portfolio beyond its existing core franchises. Vertex Pharmaceuticals has built its business around treatments for rare and serious diseases, and the planned Crinetics acquisition marks a shift into endocrinology with an FDA approved therapy and...

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S